Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
29 studies found for:    ninlaro, multiple myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Bendamustine
2 Recruiting Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: MLN9708
3 Recruiting Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
4 Recruiting A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Placebo
5 Recruiting Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
6 Recruiting BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
7 Recruiting Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Conditions: Multiple Myeloma;   High Risk Smoldering Multiple Myeloma
Interventions: Drug: Ixazomib (MLN9708);   Drug: Dexamethasone
8 Not yet recruiting Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
9 Recruiting A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Relapsed and/or Refractory Multiple Myeloma
Intervention: Drug: Ixazomib 4.0 mg, lenalidomide 25 mg, dexamethasone 40 mg
10 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
11 Not yet recruiting Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Thalidomide;   Drug: Dexamethasone
12 Recruiting Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
13 Recruiting Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
14 Recruiting Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
15 Recruiting Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Clarithromycin;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Drug: Pomalidomide
16 Recruiting Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Condition: Recurrent Plasma Cell Myeloma
Interventions: Drug: Dexamethasone;   Drug: Idasanutlin;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
17 Recruiting Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Plasma Cell Myeloma;   Transplant-Related Carcinoma
Interventions: Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
18 Recruiting Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Plasma Cell Myeloma
Interventions: Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Questionnaire Administration
19 Recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
20 Recruiting UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
Condition: Multiple Myeloma
Intervention: Drug: Ixazomib

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.